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Background: Hepatitis B virus (HBV) and Hepatitis C virus (HCV) co-infections among HIV-1 infected individuals are
growing worldwide health problems characterized by lack of effective vaccines, need for expensive treatment,
chronicity of morbidity and associated mortality. Their prevalence and distribution patterns continue to vary across
geographical locations with high prevalence being detected among high risk populations. To determine the
prevalence of HBV and HCV among HIV-1 infected individuals, blood samples were collected from consenting study
subjects visiting comprehensive HIV clinics in Nairobi during the period between October and December 2009.
Methods: Blood samples from volunteers were screened with ELISA tests for detecting HIV, HBV surface antigen
(HBsAg) and anti-HCV antibodies.
Results: In a total of three (300) hundred infected individuals consisting of 129 (43%) males and 171 (57%) females
15.3% (46/300) were HIV-1 co-infected with either HBV or HCV or both, 10.3% (31/300) with HIV-1 and HCV and 6%
(18/300) with HIV-1 and HBV infections. However, only three individuals (1%) were coinfected with the three viruses
(HIV/HBV/HCV).
Conclusion: Though, low levels of co-infection with all three viruses were reported, there could be higher
prevalence rates than reported here especially among high risk populations.
Keywords: Hepatitis, HIV-1, ELISABackground
Human immunodeficiency Virus (HIV), Hepatitis B virus
(HBV), and Hepatitis C virus (HCV), are the three most
common chronic viral infections all over the world. They
share similar transmission routes including sexual, blood-
blood contact, and injecting drug usage [1,2]. Co-infection
with HIV and HCV and/or HBV is very common in
certain populations, such as intravenous drug users (IDUs)
who often share the contaminated needles/syringes for
intravenous drug injection. It has been reported that the
world prevalence of HIV-HCV co-infection among IDUs
can surpass 90% in certain populations [3,4]. Besides,* Correspondence: akibera2000@gmail.com
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stated.the rates of HIV-HBV co-infection are reported as high
as 10–20% in countries where HBV infection is either
endemic or intermediate to high HBV cases [5]. It has
been observed that HBV/HIV co infection leads to in-
creased morbidity and mortality as compared to HIV or
HBV mono-infections [5]. The ever increasing burden
of these infections has become a growing concern [6].
With increased access to antiretroviral drugs for HIV
patients, migrating populations and social networking
by intravenous drug use, cases of HBV and HCV co
infections have been on the rise [7], coupled with the
dramatic rise in survival rates of these individuals [8].
As a result of these factors, cases of hepatic diseases
have also been on the rise [9]. Studies show that HIV co
infection adversely impacts on the natural history of
HBV and HCV [7] by accelerating progression to
chronic live disease due to drug-related hepatotoxicityLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Characteristics of HIV positive, HIV/HCV and HIV/HBV co-infected individuals
Categories All n=(300) Male Female HIV-1 only HIV-1/HBV HIV-1/HCV HIV-1/HBV/HCV p=value
Age(yrs)[mean (S.D)] 33.9 (9.1) 35.7 (8.7) 32.6 (9) 34.24 (9.138) 34.8 (6.5) 30.6 (8.3) 33.3 (7.2) 0.001
CD4+ T cell count
(Cells/mm3) (Mean)
388 (±262.95) 375 (±250.2) 398 (±226.9) 400.7 (±270.1) 252.2 325.8 (±228.7) 576.7 (±213.5) 0.02
HBV (%) 10/18 (55%) 8/18 (45%)
HCV (%) 14/30 (46.7%) 16/30 (53.3%)
Patients [n] (%) 300 (100) 129 (43.0) 171 (57) 248 (82.7) 18 (6) 30 (10%) 3 (1)
Muriuki et al. BMC Research Notes 2013, 6:363 Page 2 of 6
http://www.biomedcentral.com/1756-0500/6/363and hepatitis reactivation [10-12]. At this stage, most
patients are likely to die due to liver-related diseases
compared to those without HIV infection [13].
In Kenya, the HIV-1 epidemic has been well docu-
mented. However, little data exists on HBV and HCV
co infection among HIV-1 positive patients [14]. This
study was carried out among HIV positive patients
who were accessing CD4 testing services, to determine
the levels of HBV and HCV co infections. This was
done with the knowledge that such patients are at a
high risk of a rapid disease progression coupled with
development of liver cirrhosis and hepatocellular car-
cinoma [15].Table 2 Prevalence of HIV-1, HBV, HCV coinfections by
age and CD4+ counts
Age
group
(n/300) HIV HBV/HCV HBV HCV Average CD4
count
1-5 2 2 - - - 1211
6-10 2 1 - - 1 370
11-15 2 2 - - - 537
16-20 4 3 - - 1 409
21-25 40 31 1 2 6 461
26-30 73 61 - 4 8 (11.1) 401
31-35 61 52 - 3 6 350
36-40 48 35 2 5 6 (12.8) 356
41-45 40 34 - 4 2 380
46-50 18 17 - - 1 272
51-55 10 10 - - - 432
56-60 3 3 - - - 352
Total 300 248 3 18 31Methods
Between October and December 2009, a cross sectional
study was carried out involving three (300) hundred
consenting HIV-1 infected patients. The volunteers were
recruited after providing written consent i.e. for persons
aged above 18 years and assent from guardians and
mothers of persons aged below 18 years. The enrolled
volunteers were aged between 4–59 years of age. The
participants were recruited through stratified sampling
from nine Nairobi-based health centres namely; Baraka,
Ngong, Pumwani, Ongata Rongai, Kangemi, Huruma,
Kamiti, Ngaira and Waithaka. Blood was collected asep-
tically into 10 ml vacutainer tubes (Becton Dickson,
New Jersey USA) for biochemical, CD4+ count and viral
serology tests. The CD4+ T lymphocytes assay was
performed within three hours of collection, while serum
for serological assays for hepatitis C and B markers was
stored at −20°C until the time for assay [16]. CD4+T
lymphocytes count was determined by flow cytometry
using Becton Dickson Facs calibur machine [17]. The
determination of anti hepatitis C virus IgG antibody
(anti HCV) and Hepatitis B antigen (HBsAg) were
conducted by use of antibody capture ELISA, enzyme-
linked immunosorbent assay kit (Hepanostika HBsAg)
(Murex Biotech Ltd, Dartford, UK) [18] and Murex anti-
HCV kit for Hepatitis C virus, (Murex anti-HCV version
4.0) [19]. HIV-1 and HIV-2 Vironostika HIV Uni-Form
II Ag/Ab (Bio-Merieux, Boxtel, The Netherlands) follow-
ing the manufacturer’s instructions.Ethical considerations
This study was ethically approved by Kenya Medical
Research Institute (KEMRI) National Scientific Steering
Committee SCC reference no. 1394 before it was executed.Data analysis
All generated data was entered into a database, cleaned and
analyzed using SPSS version 11.5. The sero-prevalence for
HBV and HCV were expressed as a percentage for the
entire study group. Pearsons Chi square was used to test
the association between level of immunosuppression and
HBV/HCV infection. Simple linear correlation analysis
was used to determine the association between age and
HBV/HCV infection.Results
Three (300) hundred HIV patients comprising 129
(43%) males and 171 (57%) females were enrolled in
this study. Their age ranged between 4–59 years with a
mean age of 33.92 (±8.96) years with men 36.0 (±8.7)
and 32.6 (±8.97) years for females (Table 1). There
were 48 (16%) co-infections with 18 (56%) HIV/HBV,
30 (10.%) HIV/HCV, with 3 (1%) of those infected
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ever, 248 (82.7%) were HIV monoinfected (see Table 1).
In relation to gender, there was no difference in gender
in dual infections of either HBV/HIV or HCV/HIV.
However, males had the highest prevalence rates of
HBV infection (55%) with females leading in HCVTable 3 Surveys of hepatitis B virus surface antigen (HBsAg) a
HIV-infected persons conducted in Kenya and neighboring su
Author Publication year Country Popu
Muriuki et al. (current study) 2013 Kenya Outpa
Mutuma et al. [34] 2011 Kenya Outpa
Kapembwa et al. [19] 2011 Zambia Inpati
Moore et al. [26] 2010 Malawi Inpati
Di Bisceglie et al. [35] 2010 South Africa Outpa
Mboto et al. [25] 2010 The Gambia Outpa
Kerubo et al. [23] 2010 Kenya outpa
Belay et al. [36] 2010 Ethiopia Blood
Lukhwareni et al. [37] 2009 South Africa Outpa
Oshitani et al. [38] 1996 Zambia Outpa
Harania et al. [22] 2008 Kenya Outpa
Nyirenda et al. [27] 2008 Malawi Inpati
Otegbayo et al. [28] 2008 Nigeria Outpa
Diop-Niaye et al. [30] 2008 Senegal Outpa
Shimeli et al. [39] 2008 Ethiopia Outpa
Fimhaber et al. [35] 2008 South Africa Outpa
Hoffmann et al. [40] 2008 South Africa Outpa
Nagu et al. [20] 2008 Tanzania Outpa
Pirillo et al. [29] 2007 Uganda Anten
Telatela et al. [32] 2007 Tanzania Outpa
Lesi et al. [41] 2007 Nigeria outpa
Pirillo et al. [29] 2007 Rwanda anten
Wester et al. [42] 2006 Botswana Outpa
Okoth et al. [43] 2006 Kenya Outpa
Otedo et al. [44] 2004 Kenya Outpa
Ejele et al. [45] 2004 Nigeria outpa
Rouet et al. [24] 2004 Cote d’Ivoire Anten
Mustapha et al. [46] 2004 Gombe Nigeria outpa
Kallestrup et al. [31] 2003 Zimbabwe Outpa
Kasolo et al. [47] 2003 Zambia Anten
Ampofo et al. [42] 2002 Nigeria blood
Sud et al. [48] 2001 Nigeria outpa
Lodenyo et al. [44] 2000 South Africa Outpa
Rahlenbeck et al. [49] 1997 Ethiopia outpa
Oshitani et al. [38] 1996 Zambia Outpa
Fainboim et al. [33] 1999 Argentina outpainfections (53.3%). Among those infected, majority of
them were aged 25 and 40 years (see Table 2). In
addition, the mean CD4 counts in HBV/HIV co-
infected patients were low compared to those either
HCV/HIV co-infected patients or among HIV mono-
infections (see Table 1).nd hepatitis C antibody (HCV Ab) prevalence in
b-Saharan Africa countries, 1996-2013
Prevalence rates
lation Sample size HBsAg (%) HCV (%) HCV/HBV/HIV (%)
tient 300 6 10.3
tient 51 8.8
ent 323 9.9 2.2




donors 6321 4.7 0.7
tient 192 22.9
tient 340 7.1
tient 378 6.1 1.1
ent 226 17.5 4.5
tient 1779 11.9 4.8




tient 260 17.3 18.1
atal 164 4.9 0.6
tient 15 13.8
tients 240 9.2 5.8 1.5
atal 82 2.4 4.9
tient 160 10.6
tient 15
tient 599 47 53
tient 342 9.7 1






tient 100 6 1
tients 2186 14.4
tient 340 7.1
tients 484 14.5 58.5
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With the increased access to antiretroviral therapy in re-
source limited settings, people living with HIV/AIDS will
continue to live longer. However, morbidity and mortality
due to co-infections with other viruses will increasingly
become important. Although co infections with HBV and
HCV among HIV positive patients is well documented in
developing countries, the demographics and impact of
these infections are not well defined in low resource coun-
tries like Kenya. The need for new data on hepatitis
coinfections to guide health policy is on management of
HIV coinfected a patient is paramount [19].
In this study, we examined the prevalence of HBV and
HCV among HIV infected patients seeking CD4 testing
services. From the results, it is clear that the co infection
rates of HIV-infected patients with HBV and HCV was
high (>6%). This number is high even though the study
participants were persons who were seeking CD4 testing
services i.e. probably immunosuppressed and not repre-
sentative of the general population. This has an indication
that hepatitis infection in HIV-infected persons may be
higher than that of the general population. Co –infection
with HCV was also high (10%). This was higher than what
we could expect in the general population i.e. about 5%
[20,21]. Compared to previous studies in Kenya on similar
populations, these findings were contrarily higher 1.1%
[22]; 0.7% [23], including those from Zambia (2.2%) [19],
Cote d’voire (1.2%) [24], Gambia (0.6%) [25], Malawi
(5.7%) [26,27], Nigeria (4.8%) [28], Rwanda (4.9%) [29],
Senegal (1.6%) [30] Uganda (0.6%) [31] and Zimbabwe
(0.8%) [31] (Table 3). The higher rates could probably due
to increased free access to antiretroviral therapy and di-
verse study subjects. However, the high estimate of HCV
prevalence among HIV infected patients in this study were
similar to those obtained in Tanzania; [21,32] but less to
those obtained in Argentina [33].
The HIV/HBV co infection rates (6%) detected in this
study was found to be consistent with findings from other
studies carried out in Kenya [22,50], Zambia [19,34], Cote
d’ Ivore [24], Malawi [25], Nigeria [38], Ethiopia [41] and
South Africa [39]. However, these findings were low com-
pared to those previous obtained in Kenya (55.8%) among
liver failure patients [43,44] Tanzania [32,51], Zambia [47],
Botswana [42], Malawi [27], Nigeria [28,42,46,48], Ethiopia
[40], Argentina [34] South Africa [37,40] (Table 3). These
prevalence rates were also found to be higher than those
obtained in Ethiopia [35,52], South Africa [35,53], Uganda
and Rwanda [29]. The observed diverse prevalence rates
across different countries were associated with the diver-
sity of patients from different population groups, sample
size, test kit sensitivity and specificity [52].
The HIV co-infection rates as per gender in this study
was found not to be significantly higher among male
study subjects (19.2%) as compared to their femalecounterparts (14.3%) (p>0.061). This finding was com-
parable to reports from elsewhere [22]. This observation
may have been accounted for by the fact that men are
more likely to have multiple sex partners and also practice
unprotected sex due to the polygamous nature of their
relationships.
We also observed a significant high prevalence in HCV
antibody among HIV infected patients. The probable rea-
son could be due to the shared modes of transmission of
both viruses in the study patients. The prevalence of HIV/
HCV was also found to be higher in Males (11.6%) as
compared to females (9.4%). However, the difference was
not significant (p>0.055). This observation was similar to
previous studies conducted in Kenya [23], Nigeria [4,21]
and contrarily to other findings of older females being
more co- infected [23,51].
Three patients (1%) were found co-infected with trio
HIV, HBV and HCV infections in this study. These findings
were similar to those obtained previously in Kenya [23,25],
Nigeria [53] and Ethiopia [29] indicating a maintained
low rates of these trio infections [22,23,25,35,36] (Table 3).
Conclusions
In spite of carrying out the study only among HIV-
infected patients, it was evident that co-infection rates
with HIV and HCV and/or HBV are higher among HIV
infected individuals than populations that are HIV nega-
tive. There is therefore a need for constant surveillance of
these infections that pose a challenge in vaccine design
and treatment options.
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